Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer

In order to explore the efficacy of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer, 100 patients with triple negative breast cancer who met the screening criteria were divided into two groups according to the random number table method. One group was treated with albumin bound paclitaxel and cisplatin chemotherapy as the conventional chemotherapy group, and the other group was treated with anlotinib Hydrochloride Capsules on the basis of the conventional chemotherapy group. Both groups were treated for 6 cycles. After half a year of treatment, compared with the conventional chemotherapy group, the Orr and CBR of the combined drug treatment group were significantly increased, and the levels of bone sialoprotein (BSP), prolactin (PRL), insulin like growth factor-1 (IGF-1) and angiopoietin-2 (Ang-2) were significantly decreased, the difference was statistically significant. There were no serious adverse events in the two groups during the treatment, and there was no significant difference in the incidence of adverse reactions between the two groups; The deadline for follow-up of all patients was June 2023, and the follow-up time was 8–36 months. The medianProgression-free survival (PFS) of patients in the conventional chemotherapy group was 29.38 months (95% CI: 26.918–31.842), and the median PFS of patients in the combined drug treatment group was 33.72 months (95% CI: 32.417–35.023). There was a statistically significant difference in survival between the two groups (Log rank = 4.072, p = 0.044). The curative effect of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer is significant, which can effectively reduce the level of relevant serum factors, has high safety, and is helpful to improve the survival of patients.

Triple negative breast cancer; Anlotinib; Chemotherapy; Safety; Efficacy

[1] Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. British Journal of Hospital Medicine. 2022; 83: 1–7.

[2] Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese Medical Journal. 2022; 135: 584–590.

[3] Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Communications. 2021; 41: 1183–1194.

[4] Tsang JYS, Tse GM. Molecular classification of breast cancer. Advances in Anatomic Pathology. 2020; 27: 27–35.

[5] Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review of Anticancer Therapy. 2021; 21: 135–148.

[6] Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metabolism. 2023; 35: 84–100.e108.

[7] Popovic LS, Matovina-Brko G, Popovic M, Punie K, Cvetanovic A, Lambertini M. Targeting triple-negative breast cancer: a clinical perspective. Oncology Research. 2023; 31: 221–238.

[8] Latif F, Bint Abdul Jabbar H, Malik H, Sadaf H, Sarfraz A, Sarfraz Z, et al. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert Review of Anticancer Therapy. 2022; 22: 229–235.

[9] Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. Journal of Medicine and Life. 2022; 15: 153–161.

[10] Lv B, Chen J, Liu XL. Anlotinib-induced hypertension: current concepts and future prospects. Current Pharmaceutical Design. 2022; 28: 216–224.

[11] Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clinical Cancer Research. 2022; 28: 793–809.

[12] Li Q, Liu J, Jiang Z, Liu Q. CSCO breast cancer guideline: precise, economical and oriental. Science China Life Sciences. 2020; 63: 1410–1412.

[13] Marazzi F, Orlandi A, Manfrida S, Masiello V, Di Leone A, Massaccesi M, et al. Diagnosis and treatment of bone metastases in breast cancer: radiotherapy, local approach and systemic therapy in a guide for clinicians. Cancers. 2020; 12: 2390.

[14] Jiang J, Jiang S, Ahumada-Canale A, Chen Z, Si L, Jiang Y, et al. Breast cancer screening should embrace precision medicine: evidence by reviewing economic evaluations in China. Advances in Therapy. 2023; 40: 1393–1417.

[15] Jiang H, Zhang R, Liu X, Ran R, Zhang J, Liu Y, et al. Bilateral breast cancer in China: a 10-year single-center retrospective study (2006–2016). Cancer Medicine. 2021; 10: 6089–6098.

[16] Jokar N, Velikyan I, Ahmadzadehfar H, Rekabpour SJ, Jafari E, Ting HH, et al. Theranostic approach in breast cancer: a treasured tailor for future oncology. Clinical Nuclear Medicine. 2021; 46: e410–e420.

[17] Su H, Li X, Lv Y, Qiu X. Breast cancer epidemiology and survival analysis of Shenyang in Northeast China: a population-based study from 2008 to 2017. The Breast Journal. 2022; 2022: 6168832.

[18] Tao X, Li T, Gandomkar Z, Brennan PC, Reed WM. Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries. Asia-Pacific Journal of Clinical Oncology. 2023; 19: 645–654.

[19] Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nature reviews. Clinical Oncology. 2022; 19: 91–113.

[20] Zhao S, Wang P, Yin F, Wu J, Wang Y, Li P, et al. Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib. Tumori Journal. 2023; 109: 186–196.

[21] Lasica M, Tam CS. Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America. 2021; 35: 761–773.

[22] Dybowski S, Torke S, Weber MS. Targeting B cells and microglia in multiple sclerosis with Bruton tyrosine kinase inhibitors: a review. JAMA Neurology. 2023; 80: 404–414.

[23] Marra A, Curigliano G. Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. The Cancer Journal. 2021; 27: 41–49.

[24] Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, et al. Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics. 2020; 10: 6839–6853.

[25] Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. Journal of Clinical Oncology. 2022; 40: 1795–1805.

[26] Kriegel A, Langendorf E, Kottmann V, Kammerer PW, Armbruster FP, Wiesmann-Imilowski N, et al. Bone sialoprotein immobilized in collagen type I enhances angiogenesis in vitro and in ovo. Polymers. 2023; 15: 1007.

[27] Dehdari H, Moradian F, Barzegar A, Ebrahimzadeh MA. CYP1A1 contiguous hypermethylation within a putative CpG block is associated with breast cancer progression: feasibility to define boundary motives. Experimental Cell Research. 2022; 413: 113062.

[28] Carrasco-Ceballos JM, Barrera-Hernandez D, Locia-Espinosa J, Sampieri CL, Lara-Reyes JA, Hernandez-Aguilar ME, et al. Involvement of the PRL-PAK1 pathway in cancer cell migration. Cancer Diagnosis & Prognosis. 2023; 3: 17–25.

[29] Sair AT, Liu RH. Molecular regulation of phenolic compounds on IGF-1 signaling cascade in breast cancer. Food & Function. 2022; 13: 3170–3184.

[30] Yan Y SQ, Yao L, Zhao L, Cai H. YAP overexpression in breast cancer cells promotes angiogenesis through activating YAP signaling in vascular endothelial cells. Analytical Cellular Pathology. 2022; 2022: 5942379.